DZD2269

DZD2269 is a potent and selective small molecule antagonist of the adenosine A2A receptor (A2AR; also known as ADORA2A), developed as an immune checkpoint inhibitor with immunomodulating and antineoplastic activities. By selectively binding to and inhibiting A2AR expressed on T lymphocytes, DZD2269 reverses adenosine-induced immunosuppression in the tumor microenvironment, thereby restoring immune cell function. Preclinical studies have shown that DZD2269 can enhance antitumor activity when combined with anti-PD1 antibodies or radiotherapy. Clinical trials are ongoing to evaluate its safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy in patients with metastatic castration-resistant prostate cancer[1][2][5][7].